Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

1. Metformin shows early promise for controlling clozapine-related weight gain

Metformin shows early promise for controlling clozapine-related weight gain Signal - Metformin shows early promise for controlling clozapine-related weight gain Dissemination Centre Discover Portal NIHR DC Discover Metformin shows early promise for controlling clozapine-related weight gain Published on 30 August 2016 People with schizophrenia who were taking clozapine had greater weight loss, reductions in waist circumference, and lower glucose and triglycerides, when given metformin compared (...) if these treatments are unsuccessful. SIGN guidelines recommend considering the use of metformin, and this review suggests it is likely to be beneficial, though this is early stage research. Share your views on the research. Why was this study needed? Schizophrenia is a serious and chronic mental health condition. It affects around 1 in 100 people in their lifetime. Many respond to initial drug treatment but around 20% of people do not respond sufficiently well. After two attempts with different antipsychotic

2019 NIHR Dissemination Centre

2. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes

Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes 30499237 2019 01 03 1463-1326 2018 Nov 30 Diabetes, obesity & metabolism Diabetes Obes Metab Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. 10.1111/dom.13594 (...) To compare the efficacy and safety of an intensification strategy of early triple combination therapy with dapagliflozin (DAPA) plus saxagliptin (SAXA) to a dual therapy strategy with sitagliptin (SITA) in patients with type 2 diabetes who are inadequately controlled with metformin (MET) monotherapy. This multinational, active-controlled, parallel-group phase 3b trial randomized 461 patients, at least 18 years of age, with glycated haemoglobin (HbA1c) of 8%-10.5% (64-91 mmol/mol), to either DAPA plus

2019 EvidenceUpdates

3. Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus

Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus 30566007 2018 12 19 1524-4539 138 25 2018 Dec 18 Circulation Circulation Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus. 2895-2907 10.1161/CIRCULATIONAHA.118.035525 Cardiovascular disease is the leading cause of mortality in type 1 diabetes mellitus (T1DM) and relates strongly to insulin resistance (IR). Lean and obese adolescents with T1DM have (...) marked IR. Metformin improves surrogate markers of IR in T1DM, but its effect on directly measured IR and vascular health in youth with T1DM is unclear. We hypothesized that adolescents with T1DM have impaired vascular function and that metformin improves this IR and vascular dysfunction. Adolescents with T1DM and control participants underwent magnetic resonance imaging of the ascending (AA) and descending aorta to assess pulse wave velocity, relative area change, and maximal (WSS MAX ) and time

2019 EvidenceUpdates

4. Type 2 diabetes: what's next after metformin?

Type 2 diabetes: what's next after metformin? Type 2 diabetes: what's next after metformin? | NPS MedicineWise 20 Years Of Helping Australians Make Better Decisions About Medicines, Medical Tests And Other Health Technologies. Log in Facebook Twitter LinkedIn Google Signing you in Use another account OR Login Form Email Password Log in to NPS MedicineWise Forgot password Forgot password Email Send reset instructions Set new password Reset Password Password Set password Account exists We found (...) that match your past search terms. We’ll send you email alerts for articles that match these search terms: History Clear all to view your search history. Menu Breadcrumbs Type 2 diabetes: what's next after metformin? Type 2 diabetes: what's next after metformin? With a range of blood glucose-lowering medicines on the market, it can be hard to decide what to prescribe for patients needing more than metformin. Share Share to: Larger text Smaller text This program is funded by Boehringer Ingelheim Pty

2019 National Prescribing Service Limited (Australia)

5. Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial

Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial 30362280 2018 10 26 1463-1326 2018 Oct 26 Diabetes, obesity & metabolism Diabetes Obes Metab Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial. 10.1111/dom.13566 To assess the efficacy (...) and safety of add-on therapy with the dipeptidyl peptidase-4 inhibitor teneligliptin compared with sitagliptin in patients with type 2 diabetes (T2DM) inadequately controlled with metformin and glimepiride. This was a phase 3, randomized, double-blind, non-inferiority study of adult Korean subjects with T2DM (n=201), with glycated hemoglobin (HbA1c) ranging from 7.0-11.0%, on stable doses of metformin plus glimepiride. Subjects were randomized in a 1:1 fashion to receive either oral teneligliptin 20 mg

2018 EvidenceUpdates

6. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial

Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial 30129089 2018 10 08 1463-1326 2018 Aug 21 Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label (...) , randomized phase III trial. 10.1111/dom.13506 To compare the efficacy and safety of once-weekly dulaglutide with that of insulin glargine in combination with metformin and/or a sulphonylurea in mainly Asian patients with type 2 diabetes mellitus (T2DM). In this 52-week, randomized, parallel-arm open-label study, we enrolled patients aged ≥18 years with T2DM for at least 6 months and a glycated haemoglobin (HbA1c) concentration ≥53.0 mmol/mol (7.0%) and ≤96.7 mmol/mol (11.0%). The primary outcome

2018 EvidenceUpdates

7. A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral anti

A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral anti 29961975 2018 08 03 1463-1326 2018 Jul 02 Diabetes, obesity & metabolism Diabetes Obes Metab A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin (...) with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study. 10.1111/dom.13454 To confirm non-inferiority of biphasic insulin aspart 30 (BIAsp 30) plus metformin to BIAsp 30 in lowering glycated haemoglobin (HbA1c) in Chinese patients with inadequately controlled type 2 diabetes using oral antidiabetic drugs. In this 16-week, prospective, randomized, open-label, multicentre, parallel-controlled study, patients aged 18-79

2018 EvidenceUpdates

8. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled 30082326 2018 08 07 1935-5548 2018 Aug 06 Diabetes care Diabetes Care Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled (...) With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial. dc180680 10.2337/dc18-0680 Among patients with type 2 diabetes uncontrolled with metformin, exenatide once weekly (QW) plus dapagliflozin combination produced greater reductions in glycemia, weight, and systolic blood pressure (SBP) at 28 weeks than exenatide QW or dapagliflozin alone (DURATION-8). Here, we investigated the safety and maintenance of efficacy at 52 weeks, after a 24-week extension. This phase 3

2018 EvidenceUpdates

9. Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study (PubMed)

Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study 30151369 2018 11 14 2312-0541 4 3 2018 Jul ERJ open research ERJ Open Res Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study. 00060-2018 10.1183/23120541.00060-2018 Pulmonary arterial hypertension (PAH) is a common complication of a congenital heart defect (CHD (...) ). Recent studies suggest metformin may be a potential drug to improve cardiac function in PAH. A pilot study was conducted to investigate the efficacy of short-term treatment with a combination regimen consisting of bosentan and metformin in PAH-CHD patients as compared with bosentan monotherapy in a prospective, randomised study. Patients with PAH-CHD were randomised to receive bosentan (initially at 62.5 mg twice daily for 4 weeks and then 125 mg twice daily) for 3 months with or without

Full Text available with Trip Pro

2018 ERJ open research

10. Giving obese pregnant women metformin had no effect on baby’s weight at birth

Giving obese pregnant women metformin had no effect on baby’s weight at birth Signal - Giving obese pregnant women metformin had no effect on baby’s weight at birth Dissemination Centre Discover Portal NIHR DC Discover Giving obese pregnant women metformin had no effect on baby’s weight at birth Published on 15 September 2015 A large trial found that giving obese pregnant women the diabetes drug, metformin, to prevent heavier babies, had no effect compared with an inactive dummy tablet (...) . The trial was funded by the NIHR and Medical Research Council, and was the first to give metformin, a diabetes drug that is safe in pregnancy, to pregnant women without type 2 diabetes for this purpose. There are theoretical reasons why the medication may help in reducing a baby’s birthweight and previous studies had shown links between higher glucose levels in mother’s blood and larger babies. Participants received either standard doses of metformin or the inactive tablet from about 12 weeks

2018 NIHR Dissemination Centre

11. Metformin

Metformin Top results for metformin - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for metformin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

2018 Trip Latest and Greatest

12. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes 29947099 2018 07 17 1463-1326 2018 Jun 27 Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. 10.1111/dom.13437 To compare the efficacy and safety of dapagliflozin and dapagliflozin plus saxagliptin vs (...) glimepiride as add-on to metformin in patients with type 2 diabetes. This 52-week, multicentre, double-blind, active-controlled study (NCT02471404) randomized (1:1:1) patients (n = 939; HbA1c 7.5%-10.5%) on metformin monotherapy (≥1500 mg/day) to add-on dapagliflozin 10 mg, dapagliflozin 10 mg plus saxagliptin 5 mg, or glimepiride 1 to 6 mg (titrated). The primary efficacy end point was change in HbA1c from baseline to Week 52. Baseline mean age, diabetes duration and HbA1c were 58.4 years, 7.0 years

Full Text available with Trip Pro

2018 EvidenceUpdates

13. A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin

A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin 30026333 2018 07 20 1935-5548 2018 Jul 19 Diabetes care Diabetes Care A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin. dc172381 10.2337/dc17-2381 (...) To investigate the efficacy and safety of once-daily semaglutide in comparison with once-daily liraglutide and placebo in patients with type 2 diabetes. This 26-week, multicenter, double-blind trial involved patients diagnosed with type 2 diabetes with HbA 1c 7.0-10.0% (53-86 mmol/mol) and treated with diet and exercise with or without metformin. Patients were randomized 2:2:1 to once-daily semaglutide, liraglutide, or placebo in one of four volume-matched doses (semaglutide 0.05, 0.1, 0.2, or 0.3 mg

2018 EvidenceUpdates

14. Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes. (PubMed)

Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes. BACKGROUND: There has been considerable interest in providing antenatal dietary and lifestyle advice for women with obesity or who are overweight during pregnancy, as a strategy to limit gestational weight gain and improve maternal and infant health. However, such antenatal interventions appear to have a modest effect on gestational weight gain and other clinical pregnancy and birth (...) outcomes and additional strategies are required.Metformin is an oral insulin-sensitising medication that acts to decrease blood glucose concentrations. Metformin is commonly used in the treatment of type 2 diabetes mellitus and polycystic ovarian syndrome, and is being used increasingly in the treatment of gestational diabetes, having been shown to result in decreased rates of caesarean birth and neonatal hypoglycaemia. Metformin may be an adjuvant therapy to current antenatal strategies in pregnant

2018 Cochrane

15. Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study

Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study 29868840 2018 07 05 2168-6114 178 7 2018 Jul 01 JAMA internal medicine JAMA Intern Med Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study. 903-910 10.1001/jamainternmed.2018.0292 Approximately 1 million patients in the United States with type 2 diabetes mellitus and mild-to-moderate kidney disease (...) do not receive guideline-directed therapy with metformin. This may reflect uncertainty regarding the risk of acidosis in patients with chronic kidney disease. To quantify the association between metformin use and hospitalization with acidosis across the range of estimated glomerular filtration rate (eGFR), accounting for change in eGFR stage over time. Community-based cohort of 75 413 patients with diabetes in Geisinger Health System, with time-dependent assessment of eGFR stage from January 2004

2018 EvidenceUpdates

16. Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study. (PubMed)

Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study. OBJECTIVE: To investigate whether exposure to metformin during the first trimester of pregnancy, for diabetes or other indications, increases the risk of all or specific congenital anomalies. DESIGN: Population based exploratory case-control study using malformed controls. Cases of 29 specific subgroups of non-genetic anomalies, and all non-genetic anomalies (...) birth, and maternal diabetes status. RESULTS: 168 babies affected by congenital anomaly (141 non-genetic and 27 genetic) were exposed to metformin, 3.3 per 1000 births. No evidence was found for a higher proportion of exposure to metformin during the first trimester among babies with all non-genetic anomalies combined compared with genetic controls (adjusted odds ratio 0.84, 95% confidence interval 0.55 to 1.30). The only significant result was for pulmonary valve atresia (adjusted odds ratio 3.54

Full Text available with Trip Pro

2018 BMJ

17. Validation of the Survival Benefits of Metformin in Middle Eastern Patients With Type II Diabetes Mellitus and Colorectal Cancer (PubMed)

Validation of the Survival Benefits of Metformin in Middle Eastern Patients With Type II Diabetes Mellitus and Colorectal Cancer 30084749 2018 12 07 2378-9506 4 2018 Jul Journal of global oncology J Glob Oncol Validation of the Survival Benefits of Metformin in Middle Eastern Patients With Type II Diabetes Mellitus and Colorectal Cancer. 1-10 10.1200/JGO.18.00018 Purpose Epidemiologic data from several populations suggest that metformin may decrease cancer risk and mortality in patients (...) with colorectal cancer (CRC) and type II diabetes mellitus (DM). Although type II DM and CRC are major health problems in the Middle East, no investigations have been performed to test the effect metformin has on the outcome of patients with type II DM and CRC who are also treated with metformin. Materials and Methods We retrospectively reviewed the medical records of 1,902 patients diagnosed with CRC at King Hussein Cancer Center between January 2004 and December 2012, and identified 349 patients (18

Full Text available with Trip Pro

2018 Journal of global oncology

18. Spotlight: A case of Metformin Associated Lactic Acidosis

Spotlight: A case of Metformin Associated Lactic Acidosis Spotlight: A case of Metformin Associated Lactic Acidosis | Clinical Correlations Spotlight: A case of Metformin Associated Lactic Acidosis May 11, 2018 By Jasmine Nee and Martin Fried, MD Peer Reviewed LEARNING OBJECTIVES 1. What is metformin-associated lactic acidosis? 2. How does severe acidemia lead to acute kidney injury? 3. How do you treat metformin-associated lactic acidosis? CASE SUMMARY The patient is a 40-year-old man (...) with alcohol dependence and type II diabetes who presented to the emergency department for alcohol intoxication. After arriving hemodynamically stable with reassuring labs, he become tachypneic, confused, and lethargic a few hours later. At this point, he admitted that he took “a few” metformin pills in a suicide attempt. Arterial blood gas was significant for a pH < 6.8 and a lactate > 22 mg/dL. Due to this decompensation, he was intubated, admitted to the medical ICU, and started on hemodialysis via

2018 Clinical Correlations

19. Giving obese pregnant women metformin had no effect on baby’s weight at birth

Giving obese pregnant women metformin had no effect on baby’s weight at birth NIHR DC | Signal - Giving obese pregnant women metformin had no effect on baby’s weight at birth Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Giving obese pregnant women metformin had no effect on baby’s weight at birth Published on 15 September 2015 A large trial found that giving obese pregnant women the diabetes drug, metformin, to prevent heavier babies, had no effect compared with an inactive (...) dummy tablet. The trial was funded by the NIHR and Medical Research Council, and was the first to give metformin, a diabetes drug that is safe in pregnancy, to pregnant women without type 2 diabetes for this purpose. There are theoretical reasons why the medication may help in reducing a baby’s birthweight and previous studies had shown links between higher glucose levels in mother’s blood and larger babies. Participants received either standard doses of metformin or the inactive tablet from about

2018 NIHR Dissemination Centre

20. Metformin shows early promise for controlling clozapine-related weight gain

Metformin shows early promise for controlling clozapine-related weight gain NIHR DC | Signal - Metformin shows early promise for controlling clozapine-related weight gain Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Metformin shows early promise for controlling clozapine-related weight gain Published on 30 August 2016 People with schizophrenia who were taking clozapine had greater weight loss, reductions in waist circumference, and lower glucose and triglycerides, when (...) given metformin compared to placebo. There was no significant difference in “good” cholesterol (HDL cholesterol) or blood pressure measures. Clozapine is used to treat schizophrenia that has not responded to treatment with at least two other antipsychotics. However, it has the most negative impact on metabolic function and is strongly associated with weight gain. Current UK practice is to treat clozapine-related weight gain with lifestyle, behaviour, physical activity and diet interventions

2018 NIHR Dissemination Centre